Annamaria Brioli
@abrioli
Followers
162
Following
1K
Media
8
Statuses
151
One of the main goals of our review article in @NEJM on MGUS was to provide clear clarifications on the concept of “monoclonal gammopathy of clinical significance” (MGCS). It’s all very confusing in the literature and can cause problems for patients if we are not totally clear of
nejm.org
MGUS is a common, asymptomatic plasma-cell disorder in older adults that can progress to cancer or systemic illness. Diagnosis warrants follow-up, but treatment is not required unless progression i...
6
78
251
CAR T-cell therapy for the beast that is plasma cell leukemia #PCL. 👏 led by Doug Sborov and team at @huntsmancancer
https://t.co/zkIEFxmRtc
0
21
56
Very important recommendations on CML. A must read
Just published: on behalf of the European LeukemiaNet, the international expert panel led by Prof Jane Apperley presented the 2025 management recommendations of chronic myeloid leukemia (CML) in LEUKEMIA @LeukemiaJnl open access. https://t.co/m97NicZLcC
0
0
1
⏰ Don’t miss out! Join our next iCMLf Conversation: CML Highlights of EHA2025 🗓️ July 22 | 14:00 CEST Prof. Tomasz Stokłosa and Prof. Andreas Hochhaus will share key insights from EHA2025. Register now: https://t.co/GzkkakApyp
0
2
3
The paper of the day: a landmark publication that is bound to serve as a reference for years to come! @NatRevClinOncol @thanosdimop @COMyCongress @TheIACH @mbeksac56
1
55
158
If you don’t have time to take a walk, then you don’t have time to do science. Charles Darwin would take two walks every day on his "thinking path", not as a break from science, but as a crucial part of it.
6
60
386
📢 The new EMN guideline paper on T-cell immunotherapy for #MutlipleMyeloma is now available online in the #LancetHaematology journal! 📰 Thank you Niels van de Donk and Hermann Einsele for leading this important work! Check it out here 👉
thelancet.com
Novel T-cell immunotherapies (chimeric antigen receptor [CAR] T cells and T-cell redirecting bispecific antibodies) are changing the treatment landscape of relapsed or refractory multiple myeloma. In...
1
7
14
Major Regulatory Milestone in MM: In response to an application by I2TEAMM and @IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @VincentRK
6
37
108
Where cardiologists and hematologists meet Joint session of @escardio with the @EHA_Hematology • Time: 20 Jun, 15:20 - 16:10 • Location: Room 2 #ESCardioOnco2025
#cardiology #hematology
0
3
11
ESC Board Cardio oncology meeting today. Shaping the future of Cardio-Oncology. The conference starts tomorrow. Do join us !
0
4
13
Ask the expert. Amazing session on long term cancer survivorship and cardiovascular risk with distinguished haematologist and cardiologists @DrRaulCordoba #ESCardioOnco2025 #EHA
1
3
7
Where cardiologists and hematologists meet: @EHA_Hematology members at the @escardio #ESCardioOnco2025: - Lydia Scarfo 🇮🇹 - Annamaria Brioli 🇩🇪 - Raul Cordoba 🇪🇸 - Mhairi Copland 🇬🇧 #hematology #cardiology #CardioOnc
1
2
9
1 in 3 cancer patients may experience serious cardiovascular side effects from treatment. For the first time, experts from cardiology, oncology, haematology, radiology, nursing and more are meeting under one roof at #ESCardioOnco2025 United by a shared mission to improve care
0
19
33
Honoured to be able to represent #EHA to discuss CVAE in elderly MM patients at the first #ESCardioOnco2025
.@abrioli gives a quick summary of her presentation on how to prevent cardiovascular adverse events in older patients with multiple myeloma. It was part of the joint session with the European Hematology Association (EHA) on 'Where cardiologists and hematologists meet'.
0
3
10
CML at EHA2025 Catch the key takeaways in our next iCMLf Conversation: CML Highlights of EHA2025 🗓️ July 22 | 14:00 CEST With leading CML experts Prof. Tomasz Stokłosa and Prof. Andreas Hochhaus. 👉 Register now: https://t.co/GzkkakApyp
0
1
7
When will I feel better? Machine learning outperforms conventional regression in predicting organ response in AL Amyloidosis. Excellent work by @johnhanna0 et al. with more to come at IMS and ASH. All collaboration welcome. #mmsm
library.ehaweb.org
EHA Library; Williams L. Jun 13 2025; 4160199;
0
4
11
🎥 In an #ISAL2025 interview, @florian_perner provided valuable insight into the mechanisms of resistance to menin inhibitors in AML and strategies to overcome resistance. Click here to watch: 👉 https://t.co/mguU3Hm7Ah 👈 #AMLsm #Leusm #Leukemia #HemOnc #ISAL25
vjhemonc.com
Florian Perner, MD, Hannover Medical School, Hannover, Germany, comments on resistance to menin inhibitors in acute myeloid leukemia (AML). He discusses point mutations and non-genetic resistance as...
0
4
7
The #IMS25 preliminary program is available! Don’t miss out—register now! https://t.co/hwMxoOgoMc
#Myeloma #Toronto2025 📑
1
11
16
We stop all premeds (steroids, antihistamines, and acetaminophen) after cycle 1 for both IV and SQ dara. If someone has had reactions with even the last dose of cycle 1, then for that patient, these may be continued, but otherwise no. Here is a paper on our experience.
ascopubs.org
PURPOSEDaratumumab is an anti-CD38 monoclonal antibody used to treat multiple myeloma and light chain amyloidosis. Because daratumumab may cause reactions after intravenous or subcutaneous (SC)...
For those reducing dexamethasone in patients on DRd or Dara monotherapy, do you stop Dex pre-meds before Daratumumab? Have you seen increased infusion reactions? And for DRd, what thromboprophylaxis do you use if Dex is reduced/stopped? #myeloma #downwithdex
4
34
100